Drug data last refreshed 9h ago · AI intelligence enriched 5d ago
Sodium nitrite is an intravenous solution indicated for cyanide poisoning treatment as part of the cyanide antidote kit. It acts as a prodrug that converts hemoglobin to methemoglobin, which binds cyanide and facilitates its elimination. This is a specialized acute-care therapeutic with limited but critical use in emergency medicine and toxicology.
Niche acute-care product with minimal commercial infrastructure; limited team expansion expected as patent expires in 5.3 years.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite
Sodium Nitrite to Treat Arterial Aging
Pilot Study of Sodium Nitrite in Resuscitated Cardiac Arrest Patients
Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease
Sodium Nitrite in Acute Myocardial Infarction
Worked on SODIUM NITRITE at Hope Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on sodium nitrite offers deep expertise in niche acute-care markets, regulatory maintenance, and crisis-response pharmaceutical management—valuable for specialty pharma and emergency medicine roles. However, the zero linked jobs and minimal commercial scope indicate limited career acceleration; this is best suited as a secondary portfolio product or early-career operational role.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo